$197.93
1.02% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Stock price

$197.93
+14.91 8.15% 1M
+61.13 44.69% 6M
+41.27 26.34% YTD
+12.48 6.73% 1Y
+119.88 153.59% 3Y
+156.03 372.39% 5Y
+187.29 1,760.24% 10Y
+187.29 1,760.24% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-2.04 1.02%

New AI Insights on Krystal Biotech, Inc. Insights AI Insights on Krystal Biotech, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$5.7b
Enterprise Value
$5.1b
Net debt
positive
Cash
$682.0m
Shares outstanding
28.9m
Valuation (TTM | estimate)
P/E
40.3 | 38.9
P/S
16.0 | 14.7
EV/Sales
14.1 | 13.0
EV/FCF
27.3
P/B
5.5
Financial Health
Equity Ratio
89.6%
Return on Equity
9.4%
ROCE
14.4%
ROIC
30.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$359.2m | $390.3m
EBITDA
$156.9m | $153.6m
EBIT
$151.8m | $148.3m
Net Income
$146.7m | $147.4m
Free Cash Flow
$185.4m
Growth (TTM | estimate)
Revenue
116.1% | 34.3%
EBITDA
1,335.4% | 40.7%
EBIT
3,666.7% | 43.7%
Net Income
38.5% | 65.3%
Free Cash Flow
915.1%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
43.7% | 39.4%
EBIT
42.3%
Net
40.9% | 37.8%
Free Cash Flow
51.6%
More
EPS
$4.9
FCF per Share
$6.4
Short interest
16.7%
Employees
275
Rev per Employee
$1.1m
Show more

Is Krystal Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Krystal Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Krystal Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
359 359
116% 116%
100%
- Direct Costs 24 24
107% 107%
7%
335 335
117% 117%
93%
- Selling and Administrative Expenses 128 128
25% 25%
36%
- Research and Development Expense 56 56
15% 15%
16%
157 157
1,335% 1,335%
44%
- Depreciation and Amortization 5.10 5.10
26% 26%
1%
EBIT (Operating Income) EBIT 152 152
3,667% 3,667%
42%
Net Profit 147 147
39% 39%
41%

In millions USD.

Don't miss a Thing! We will send you all news about Krystal Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Krystal Biotech, Inc. Stock News

Positive
Seeking Alpha
5 days ago
Krystal Biotech (KRYS) reported strong Q3 results, with Vyjuvek delivering $97.8M revenue, 96% gross margin, and a new at-home use label. KRYS's disciplined operating expenses and robust cash position support profitability, while pipeline progress in cystic fibrosis and DEB eye therapy adds optionality. The FDA's Platform Technology Designation for KRYS's HSV-1 vector accelerates development, e...
Neutral
Seeking Alpha
5 days ago
Krystal Biotech, Inc. ( KRYS ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Stephane Paquette - Vice President of Corporate Development Krish Krishnan - Founder, Chairman, President & CEO Laurent Goux - Senior VP & GM of Europe Suma Krishnan - Founder, President of R&D and Director Kathryn Romano - Executive VP & Chief Accounting Officer Conference Call Participants J...
Neutral
GlobeNewsWire
about 2 months ago
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) approved a label update for VYJUVEK® (beremagene geperpavec-svdt) that expands the VYJUVEK eligible patient pop...
More Krystal Biotech, Inc. News

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Krish Krishnan
Employees 275
Founded 2016
Website www.krystalbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today